Protein-Synthesizing GTPase (Elongation Factor) (P17025)

Target Name: Protein-Synthesizing GTPase (Elongation Factor)

NCBI ID: P17025

Protein-Synthesizing GTPase (Elongation Factor)

Other Name(s): None

Protein-Synthesizing GTPase (Elongation Factor)

Protein-synthesizing GTPase (Elongation Factor) (nonspecified subtype) is a protein that plays a crucial role in the process of protein synthesis. This enzyme is responsible for elongating the end of the peptide chain so that it can bind to nucleic acids during protein synthesis. delivered to cells. Under normal circumstances, Elongation Factor (ESF) catalyzes GTPase activity, converts GTP into GDP and extends the peptide chain. However, some mutated ESF genes can cause problems during protein synthesis, including excess protein, poor folding, and cell death. Therefore, it is of great significance to study ESF and its variants as drug targets or biomarkers.

Variations in the ESF gene can lead to changes in protein structure and function, thereby affecting its function. For example, studies have found that mutations in the ESF gene can lead to excessive production of protein variants that can interfere with cell signaling and protein post-translational modifications. In addition, mutations in the ESF gene may also lead to poor protein folding, thereby affecting its function and stability.

Nonetheless, ESF remains a potential drug target. By inhibiting the activity of ESF, the rate of protein synthesis can be slowed down, thereby reducing the risk of protein excess and cell death. In addition, ESF can also be used as a biomarker to detect certain diseases, such as cancer and neurodegenerative diseases.

Currently, ESF has become the main focus of many studies, especially in cancer and neurodegenerative diseases. For example, some studies have shown that ESF inhibitors can slow tumor growth and extend survival. In addition, some studies have also shown that ESF can be used as a therapeutic target for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

However, ESF also has some challenges. Since ESF is a complex protein, studying the mechanism and mechanism of action of ESF is still a big challenge. In addition, there are differences in the way ESF is expressed in different cells and organisms, which may affect its role as a drug target or biomarker.

Nonetheless, ESF still has great potential as a drug target or biomarker. With the deepening of research, the molecular mechanism and mechanism of action of ESF will become clearer, thus providing a better basis for the development and utilization of ESF.

Protein Name: Protein-Synthesizing GTPase (Elongation Factor) (nonspecified Subtype)

The "Protein-Synthesizing GTPase (Elongation Factor) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Protein-Synthesizing GTPase (Elongation Factor) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets